ralA binding protein 1Genealiases: RIP1 · RLIP1 · RLIP76
Q-omics provides the consensus-scored RALBP1 profile across patient tissues and cancer cell-line models. RALBP1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, RALBP1 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RALBP1 RNA expression shows 19,632 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, KIRC, and ACC as cancer lineages where RALBP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RALBP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RALBP1 survival associations across molecular data types. RALBP1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RALBP1 RNA expression–survival associations across cancer types. High RALBP1 expression shows unfavorable associations in CESC, ACC, LGG and PAAD, but favorable associations in KIRC and UCS. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify CESC as the clearest survival context for RALBP1 RNA expression.
This table summarizes RALBP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RALBP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RALBP1 shows lower tumor expression in KIRC, KICH and THCA and higher tumor expression in LIHC, HNSC and LUSC. The KIRC box plot shows higher RALBP1 RNA expression in normal versus tumor tissue (log2 FC = −1.178, t-test p < 0.001).
This table shows molecular features associated with RALBP1 in patient tissues and cancer cell lines. In patient samples, RALBP1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, RALBP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Leukemia.
